(AMGN) Amgen - Ratings and Ratios
Arthritis, Psoriasis, Osteoporosis, Cancer, Anemia, Gout, Leukemia
AMGN EPS (Earnings per Share)
AMGN Revenue
Description: AMGN Amgen
Amgen Inc. is a leading biotechnology company that develops and delivers innovative human therapeutics worldwide, focusing on treating various serious illnesses including rheumatoid arthritis, psoriasis, osteoporosis, and certain types of cancer. Their diverse product portfolio includes blockbuster drugs such as Enbrel, Otezla, Prolia, and Repatha, among others, which are distributed through pharmaceutical wholesale distributors and direct-to-consumer channels.
From a business perspective, Amgen has established strategic collaborations with major pharmaceutical companies like AstraZeneca, Novartis, and UCB to co-develop and commercialize several key products, enhancing their pipeline and market reach. This approach not only diversifies their revenue streams but also underscores their commitment to advancing therapeutic options through partnerships.
Key Performance Indicators (KPIs) that are crucial for evaluating Amgens performance include their revenue growth, driven significantly by their top-selling products; their research and development (R&D) pipeline, which is vital for sustaining innovation and addressing unmet medical needs; and their profit margins, reflecting the companys operational efficiency. Additionally, metrics such as Return on Equity (RoE) of 92.94% indicate strong financial health and the ability to generate profits from shareholder equity. The companys forward P/E ratio of 14.20 suggests expectations of future growth, although their current P/E of 27.38 may indicate a relatively high valuation compared to projected earnings.
Amgens operational efficiency, coupled with their robust product portfolio and strategic partnerships, positions them well within the competitive biotechnology landscape. Their commitment to R&D is a critical driver of long-term value creation, with a focus on addressing significant unmet medical needs. As the company continues to execute on its pipeline and expand its market presence, investors and analysts will be closely monitoring key financial metrics, product approvals, and market dynamics to assess their future prospects.
AMGN Stock Overview
| Market Cap in USD | 152,211m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1983-06-17 |
AMGN Stock Ratings
| Growth Rating | 24.7% |
| Fundamental | 75.4% |
| Dividend Rating | 69.1% |
| Return 12m vs S&P 500 | -28.0% |
| Analyst Rating | 3.63 of 5 |
AMGN Dividends
| Dividend Yield 12m | 3.33% |
| Yield on Cost 5y | 4.45% |
| Annual Growth 5y | 7.06% |
| Payout Consistency | 100.0% |
| Payout Ratio | 43.1% |
AMGN Growth Ratios
| Growth Correlation 3m | -17.8% |
| Growth Correlation 12m | -20.2% |
| Growth Correlation 5y | 86.1% |
| CAGR 5y | 9.67% |
| CAGR/Max DD 3y | 0.39 |
| CAGR/Mean DD 3y | 1.04 |
| Sharpe Ratio 12m | 0.27 |
| Alpha | -25.65 |
| Beta | 0.485 |
| Volatility | 22.34% |
| Current Volume | 2131.1k |
| Average Volume 20d | 1886.7k |
| Stop Loss | 268 (-3%) |
| Signal | -1.76 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (6.62b TTM) > 0 and > 6% of Revenue (6% = 2.09b TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 5.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.93% (prev 18.39%; Δ -0.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 12.01b > Net Income 6.62b (YES >=105%, WARN >=100%) |
| Net Debt (48.18b) to EBITDA (15.90b) ratio: 3.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (541.0m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 64.47% (prev 63.30%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.04% (prev 34.03%; Δ 5.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.51 (EBITDA TTM 15.90b / Interest Expense TTM 2.95b) >= 6 (WARN >= 3) |
Altman Z'' 0.39
| (A) 0.07 = (Total Current Assets 26.73b - Total Current Liabilities 20.48b) / Total Assets 87.90b |
| (B) -0.29 = Retained Earnings (Balance) -25.71b / Total Assets 87.90b |
| (C) 0.12 = EBIT TTM 10.38b / Avg Total Assets 89.40b |
| (D) 0.09 = Book Value of Equity 7.43b / Total Liabilities 80.47b |
| Total Rating: 0.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.35
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 5.29% = 2.65 |
| 3. FCF Margin 30.38% = 7.50 |
| 4. Debt/Equity 7.57 = -2.50 |
| 5. Debt/Ebitda 3.54 = -2.34 |
| 6. ROIC - WACC 8.11% = 10.14 |
| 7. RoE 97.92% = 2.50 |
| 8. Rev. Trend 89.03% = 4.45 |
| 9. Rev. CAGR 12.37% = 1.55 |
| 10. EPS Trend -23.87% = -0.60 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of AMGN shares?
Over the past week, the price has changed by -1.36%, over one month by -4.02%, over three months by -5.73% and over the past year by -14.80%.
Is Amgen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMGN is around 278.11 USD . This means that AMGN is currently overvalued and has a potential downside of 0.62%.
Is AMGN a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- Strong Sell: 2
What are the forecasts/targets for the AMGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 311.9 | 12.8% |
| Analysts Target Price | 311.9 | 12.8% |
| ValueRay Target Price | 303.1 | 9.7% |
Last update: 2025-09-13 05:00
AMGN Fundamental Data Overview
CCE Cash And Equivalents = 8.03b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 23.0989
P/E Forward = 13.089
P/S = 4.3592
P/B = 20.4915
P/EG = 0.9117
Beta = 0.477
Revenue TTM = 34.91b USD
EBIT TTM = 10.38b USD
EBITDA TTM = 15.90b USD
Long Term Debt = 53.76b USD (from longTermDebt, last quarter)
Short Term Debt = 2.44b USD (from shortTermDebt, last quarter)
Debt = 56.20b USD (Calculated: Short Term 2.44b + Long Term 53.76b)
Net Debt = 48.18b USD (from netDebt column, last quarter)
Enterprise Value = 200.39b USD (152.21b + Debt 56.20b - CCE 8.03b)
Interest Coverage Ratio = 3.51 (Ebit TTM 10.38b / Interest Expense TTM 2.95b)
FCF Yield = 5.29% (FCF TTM 10.61b / Enterprise Value 200.39b)
FCF Margin = 30.38% (FCF TTM 10.61b / Revenue TTM 34.91b)
Net Margin = 18.96% (Net Income TTM 6.62b / Revenue TTM 34.91b)
Gross Margin = 64.47% ((Revenue TTM 34.91b - Cost of Revenue TTM 12.40b) / Revenue TTM)
Tobins Q-Ratio = 26.98 (Enterprise Value 200.39b / Book Value Of Equity 7.43b)
Interest Expense / Debt = 1.26% (Interest Expense 708.0m / Debt 56.20b)
Taxrate = 11.26% (519.0m / 4.61b)
NOPAT = 9.21b (EBIT 10.38b * (1 - 11.26%))
Current Ratio = 1.31 (Total Current Assets 26.73b / Total Current Liabilities 20.48b)
Debt / Equity = 7.57 (Debt 56.20b / last Quarter total Stockholder Equity 7.43b)
Debt / EBITDA = 3.54 (Net Debt 48.18b / EBITDA 15.90b)
Debt / FCF = 5.30 (Debt 56.20b / FCF TTM 10.61b)
Total Stockholder Equity = 6.76b (last 4 quarters mean)
RoA = 7.53% (Net Income 6.62b, Total Assets 87.90b )
RoE = 97.92% (Net Income TTM 6.62b / Total Stockholder Equity 6.76b)
RoCE = 17.15% (Ebit 10.38b / (Equity 6.76b + L.T.Debt 53.76b))
RoIC = 14.11% (NOPAT 9.21b / Invested Capital 65.28b)
WACC = 6.00% (E(152.21b)/V(208.42b) * Re(7.80%)) + (D(56.20b)/V(208.42b) * Rd(1.26%) * (1-Tc(0.11)))
Shares Correlation 3-Years: 46.47 | Cagr: 0.05%
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.04% ; FCFE base≈8.65b ; Y1≈9.12b ; Y5≈10.76b
Fair Price DCF = 350.1 (DCF Value 188.48b / Shares Outstanding 538.4m; 5y FCF grow 5.91% → 3.0% )
Revenue Correlation: 89.03 | Revenue CAGR: 12.37%
Rev Growth-of-Growth: -1.67
EPS Correlation: -23.87 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 123.5
Additional Sources for AMGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle